Following the decision of US health care major Abbott Laboratories and Japan's leading drugmaker Takeda to dissolve the TAP joint venture (see page 3), Alan MacKenzie has been named executive vice president of Takeda America Holdings. Mark Booth, president of Takeda Pharmaceuticals North America, will continue in this role for a certain period after completion of the integration, and Nancy Joseph-Ridge will become president of the Takeda Global R&D Center, moving up from vice president of R&D.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze